Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 75 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/23/2006 First Published: 4/1/2000


1.		Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-4697 SWOG-E4697, E4697, NCT00005034

Last Modified: 4/9/2008 First Published: 10/1/1999


2.		Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-99-C-0137 NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903

Last Modified: 11/26/2008 First Published: 3/1/2000


3.		Phase I/II Randomized Study of PR1 Leukemia Peptide Vaccine and Montanide ISA-51 in Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Over 18				NCI				MDA-DM-97325 NCI-T98-0017, NCT00004918, T98-0017

Last Modified: 9/1/2002 First Published: 5/1/2000


4.		Phase I/II Study of Human Alpha Fetoprotein Peptide Immunization in HLA-A*0201 Positive Patients With Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				UCLA-9905003 NCI-H00-0053, NCT00005629

Last Modified: 11/20/2008 First Published: 5/23/2003


5.		Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma (Phase I Closed to Accrual as of 3/29/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-03-C-0162 NCI-5855, 5855, NCT00062036

Last Modified: 2/6/2008 First Published: 7/23/2004


6.		Phase I/II Randomized Study of Vaccine Comprising Multiple Synthetic Melanoma Peptides, Montanide ISA-51, and Sargramostim (GM-CSF) in Patients With Stage IIIB, IIIC, or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				UVACC-MEL-41 UVACC-28502, UVACC-HIC-10464, NCT00089219

Last Modified: 7/19/2007 First Published: 5/23/2005


7.		Phase I/II Study of Adjuvant Vaccine Therapy Comprising Either Epstein-Barr Virus-Encoded Latent Membrane Protein (LMP)-2: 340-349 Peptide or LMP-2: 419-427 Peptide Emulsified in Montanide ISA-51 or Observation Alone in Patients With Anaplastic Nasopharyngeal Carcinoma at High Risk for Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				NCI-04-CC-0118 NCT00112541

Last Modified: 10/14/2008 First Published: 6/25/2005


8.		Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				UVACC-HIC-11491 Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274


9.		Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				Other				LUD2003-007 NCT00145158

Last Modified: 6/25/2007


10.		Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-97-C-0118 NCI-T97-0009, T97-0009

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute